Seegene Mexico
상단으로
Contáctenos

Noticias sobre productos Puedes verificar las últimas informaciones de productos

  • Launched Anyplex™ II RB5 Detection

    Anyplex™ II RB5 Detection1Simultaneous detection of 5 Respiratory bacteriaAnyplex™ II RB5 Detection detects 5 respiratory bacteria in a single real-time PCR. Mycoplasma pneumoniae (MP), Chlamydophila pneumoniae (CP), and Legionella pneumophila (LP) are the most common causes of atypical pneumonia. As these atypical pathogens do not respond to β-lactam antimicrobial therapy commonly used for bacterial community-acquired pneumonia (CAP), accurate diagnosis beyond clinical assessment is critical for determination of optimal and effective treatment. Anyplex™ II RB5 Detection has been developed using Seegene's proprietary TOCE™ Technology as a rapid and simple multiplex molecular diagnostic to simultaneously detect and differentiate CAP-related pathogens with high sensitivity and specificity. In addition, Anyplex™ II RB5 also detects and differentiates two causative agents of whooping cough, the commonly detected Bordetella pertussis(BP) as well as the less common but vaccination-ineffective Bordetella parapertussis(BPP). In addition to enabling detection and differentiation of these 5 pathogens, responsible for the respiratory bacteria infections, Anyplex™ II RB5 providing valuable information for more precise diagnosis, effective treatment and clinical follow-up.

    Aug 31, 2012 Anyplex™Ⅱ RB5 Detection

  • Launched Anyplex™ II HPV28 Detection

    Anyplex™ II HPV28 Detection Simultaneous detection of 28 HPV typesAnyplex™ II HPV28 Detection simultaneously detects 19 high-risk HPVs and 9 low-risk HPVs. Human papillomavirus (HPV) has been identified as the leading cause of cervical cancer in women, as well as a growing risk factor in oropharyngeal cancer. Although over 150 related HPV strains have been identified, only a subset have been identified as major risks factors for cervical cancer. While HPV16 and HPV18 have clearly been implicated as causative agents, the influence of other factors on the severity and progression of cervical cancer (e.g., viral load; persistence and clearance rates of virus over time) have only recently been recognized. In particular, the combination of multiple high- and low-risk HPV infections has now been identified as a risk factor to increased co-morbidity and disease progression. Outcome-based clinical studies in association with HPV vaccines studies are demonstrating the advantages of long-term monitoring for multiple viral genotypes infections in association with continued efficacy and cross-genotype protective. Unfortunately, the diagnostic tools to readily detect, identify and quantitatively assess co-infection by multiple HPV genotypes are not available. The Anyplex™ II HPV28 Detection has been specifically designed to address this unmet medical need through the simultaneous detection, identification and quantification of 28 HPV distinct genotypes (19 high-risk HPVs and 9 low-risk HPVs) contributing to cervical cancer and/or sexually transmitted infection. Based on Seegene’s proprietary DPO™ and TOCE™ technologies, this homogeneous assay performs on standard existing real-time PCR instrumentation to detect, differentiate high- or low-risk HPV infections. Anyplex™ II HPV28 Detection is a fast, reliable and quantitative solution to detection, identification and quantification of HPV infections, providing a much-needed multiplex diagnostic solution to assist in prognosis and long-term patient outcome.

    Aug 31, 2012 Anyplex™Ⅱ HPV28 Detection

  • Launched Anyplex™ II STI-7 Detection

    Anyplex™ II STI-7 Detection  Simultaneous detection of 7 STI causing pathogensAnyplex™ II STI-7 Detection detects 7 major STI causing pathogens in a single real-time PCR. Anyplex™ II STI-7 Detection enables the detection and differentiations of 7 major STI causative pathogens in a single real-time PCR reaction. The assay is based upon Seegene's proven DPO technology and its newly developed TOCE™ technology. A majority of Sexually Transmitted Infections (STI) can be asymptomatic and some have a high prevalence rate. If left untreated, they can become a major cause of diseases such as PID, extra uterine pregnancy, infertility, chronic pelvic pain, cervicitis and urethritis. Anyplex™ II STI-7 Detection is a test that not only prevents further spread of STIs but can also provide for effective STI treatments as it detects and differentiates the 7 major STI causative pathogens. Anyplex™ II STI-7 Detection is provided with on Internal control (STI-7 IC). This STI-7 IC enables the user can confirm the nucleic acid isolation and to check a possibility containig inhibitor.

    Aug 31, 2012 Anyplex™Ⅱ STI-7 Detection

  • Obtained CE-IVD marking for Anyplex™ II RV16 Detection

    Anyplex™ II  RV16 DetectionSimultaneous detection of 16 respiratory viruses Seegene's Anyplex™ II  RV16 Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Dec 23, 2011 Anyplex™Ⅱ RV16 Detection

  • Obtained CE-IVD marking for Anyplex™ plus MTB/NTM/DR-TB Detection

    Anyplex™ plus MTB/NTM/DR-TB Detection Detection and discrimination of MTB/NTM & MDR-TB Seegene's Anyplex™ plus MTB/NTM/DR-TB Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Nov 17, 2011 Anyplex™ plus MTB/NTM/DR-TB Detection

  • Simultaneous detection of 16 viruses using real-time instrumentation

    Anyplex™ RV16 Detection Multiple detection of 16 Respiratory virues using real-time instrumentation

    Oct 24, 2011 Anyplex™Ⅱ RV16 Detection

  • Obtained CE-IVD marking for Anyplex™ FluA/B Typing Real-time Detection

    Anyplex™ FluA/B Typing Real-time DetectionDetection of 2009 pandemic H1, Influenza A virus & Influenza B virus. Seegene's Anyplex™ FluA/B Typing Real-time Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Oct 21, 2011 Anyplex™ FluA/B Typing Real-time Detection

  • Obtained CE-IVD marking for Anyplex™ FluA/New H1N1 Real-time Detection

    Anyplex™ FluA/New H1N1 Real-time DetectionDetection of 2009 pandemic H1 Seegene's Anyplex™ FluA/New H1N1 Real-time Detection has been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Oct 07, 2011 Anyplex™ FluA/New H1N1 Real-Time Detection